---
title: "Weekly Recap | Tilray Brands -12.59%, consensus target above spot"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300855338.md"
description: "Tilray Brands (TLRY) fell 12.59% for the week, closing at $3.61 and underperforming the S&P 500 by about 12.32 percentage points (the index lost 0.27%). The stock opened Monday at $4.065, briefly touched $4.10, then slid across four straight sessions. It hit a weekly low of $3.54 on Thursday before a small rebound to $3.61 on Friday. Weekly amplitude was 13.78%, with daily volume running 40.8% above the 60-day median."
datetime: "2026-10-03T08:39:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300855338.md)
  - [en](https://longbridge.com/en/news/300855338.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300855338.md)
generator: "portal-rs"
---

# Weekly Recap | Tilray Brands -12.59%, consensus target above spot

## The Week

Tilray Brands (TLRY) fell 12.59% for the week, closing at $3.61 and underperforming the S&P 500 by about 12.32 percentage points (the index lost 0.27%). The stock opened Monday at $4.065, briefly touched $4.10, then slid across four straight sessions. It hit a weekly low of $3.54 on Thursday before a small rebound to $3.61 on Friday. Weekly amplitude was 13.78%, with daily volume running 40.8% above the 60-day median.

## Key Events

The most direct company news this week was Tilray-owned BrewDog naming John Beasley as chief marketing officer on Monday, continuing the build-out of its beverage management team. Several market briefs during the week noted the stock lagging the broader market but offered no new operating data. A Saturday article pulled Tilray into a broader pot-stock narrative, pointing to a 57% year-to-date decline and examining historical patterns for buying cannabis shares at the bottom. On filings, three substantive items landed on Tuesday—DEF 14A, DEFA14A, and the annual report (ARS)—all tied to shareholder and proxy voting matters.

## Analyst Ratings

Five brokers cover Tilray: two at buy, three at hold, and none at sell or under. The consensus rating is buy, with a consensus target of $7.15625, about 98.23% above the latest price of $3.61. Individual targets range from $4.00 to $17.00, signalling wide dispersion. Tilray ranks 98th among 203 names in the pharmaceutical sector.

## The Week Ahead

The main event is Tilray’s fiscal 2027 Q1 earnings on Thursday, 8 October, before the open. Consensus sees an EPS loss of $0.168 on revenue of $267m. Earlier in the week, US macro data—services PMI final, ISM non-manufacturing PMI, trade balance, and EIA crude inventories—could set the risk tone for consumer and cannabis-related names.

## In Short

Tilray pulled back this week against a backdrop of weak price action, yet the sell-side still leans buy with a consensus target well above spot. Valuation sits at roughly 0.26x price-to-book, implying the market prices the asset base cheaply, while negative EPS and the ongoing sector-wide down-draft keep pressure on. The next test is whether earnings show stabilisation on revenue and how macro prints shape risk appetite for cannabis equities.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [TLRY.US](https://longbridge.com/en/quote/TLRY.US.md)

## Related News & Research

- [Tilray’s Revolving Credit Access at Risk Under Stricter Covenant Terms, External Review Warns](https://longbridge.com/en/news/301796264.md)
- [Tilray Brands Not Dependent on Single Market, CEO Highlights Multiple Growth Engines](https://longbridge.com/en/news/301294827.md)
- [AI fever ignites a boom in thematic ETFs as fund managers hunt for their next big hit](https://longbridge.com/en/news/302963080.md)
- [Tilray Medical wins INFARMED approval for in-house quality testing at Portugal EU-GMP facility](https://longbridge.com/en/news/301699952.md)
- [Why Did Analysts Slash Bloom Energy Stock (BE) Price Targets Despite Praising Q3 Earnings Beats?](https://longbridge.com/en/news/302920834.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**